SELLAS Life Sciences Group Inc

RXK3

Company Profile

  • Business description

    SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

  • Contact

    7 Times Square
    Suite 2503
    New YorkNY10036
    USA

    T: +1 646 200-5278

    E: [email protected]

    https://www.sellaslifesciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,178.9053.700.66%
CAC 407,482.36155.892.13%
DAX 4021,961.97668.443.14%
Dow JONES (US)39,606.57419.591.07%
FTSE 1008,403.1874.580.90%
HKSE21,766.79305.83-1.39%
NASDAQ16,708.05407.632.50%
Nikkei 22535,244.41375.781.08%
NZX 50 Index12,037.8181.340.68%
S&P 5005,375.8688.101.67%
S&P/ASX 2007,972.1051.600.65%
SSE Composite Index3,292.873.48-0.11%

Market Movers